Clinical Trial Update: MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

View source ↗

Summary

Clinical trial update for the MODULA study indicates termination of a CRT therapy trial in heart failure patients with a QRS duration of 120–150 ms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• CRT device (cardiac resynchronization therapy)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Heart Failure | Status: TERMINATED